Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

Heart Failure

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

Circulation

Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi E, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators.

doi: 10.1161/CIRCULATIONAHA.120.051824

Heart Failure

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME

ESC Heart Fail.

Pellicori P, Ofstad AP, Fitchett D, Zeller C, Wanner C, George J, Zinman B, Brueckmann M, Lindenfeld J

doi: 10.1002/ehf2.12891.

Heart Failure

Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial

JAMA Cardiol.

Piotrowicz E, Pencina MJ, Opolski G, Zareba W, Banach M, Kowalik I, Orzechowski P, Szalewska D, Pluta S, Glówczynska R, Irzmanski R, Oreziak A, Kalarus Z, Lewicka E, Cacko A, Mierzynska A, Piotrowicz R

doi: 10.1001/jamacardio.2019.5006.

Cardiovascular Risk and Diseases

Echocardiographic predictors of long-term adverse cardiovascular outcomes in patients with and without diabetes mellitus: a follow-up analysis of the Copenhagen City Heart Study

Diabet Med

Özbek BT, Modin D, Møgelvang R, Jørgensen PG, Jensen MT, Schnohr P, Gislason GH, Biering-Sørensen T

doi: 10.1111/dme.14627

Cardiovascular Risk and Diseases

Echocardiographic predictors of long-term adverse cardiovascular outcomes in patients with and without diabetes mellitus: a follow-up analysis of the Copenhagen City Heart Study

Diabet Med

Özbek BT, Modin D, Møgelvang R, Jørgensen PG, Jensen MT, Schnohr P, Gislason GH, Biering-Sørensen T

doi: 10.1111/dme.14627

Heart Failure

Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial

Circ Heart Fail.

Redouane B, Greene SJ, Fudim M, Vaduganathan M, Ambrosy AP, Sun JL, DeVore AD, McNulty SE, Mentz RJ, Hernandez AF, Felker GM, Cooper LB, Borlaug BA, Velazquez EJ, Margulies KB, Sharma A

doi: 10.1161/CIRCHEARTFAILURE.

Cardiovascular Risk and Diseases

Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials

Eur Heart J.

Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P

doi: 10.1093/eurheartj/ehaa082.

Heart Failure

Impact of diabetes on clinical outcome of patients with heart failure undergoing ICD and CRT procedures: results from the German Device Registry

ESC Heart Fail.

Kaya E, Senges J, Hochadel M, Eckardt L, Andresen D, Ince H, Spitzer SG, Kleemann T, Maier SSK, Jung W, Stellbrink C, Rassaf T, Wakili R

doi: 10.1002/ehf2.12613.

Atrial FibrillationHeart Failure

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial

Eur J Heart Fail.

Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, Inzucchi SE, Fitchett D, Anker SD, Marx N, Wanner C, Zinman B, Verma S

doi: 10.1002/ejhf.1663.

Related content

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME

Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial

Echocardiographic predictors of long-term adverse cardiovascular outcomes in patients with and without diabetes mellitus: a follow-up analysis of the Copenhagen City Heart Study

Echocardiographic predictors of long-term adverse cardiovascular outcomes in patients with and without diabetes mellitus: a follow-up analysis of the Copenhagen City Heart Study

Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial

Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials

Impact of diabetes on clinical outcome of patients with heart failure undergoing ICD and CRT procedures: results from the German Device Registry

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial